# Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

> **NCT06004128** · — · NO_LONGER_AVAILABLE · sponsor: **Invivyd, Inc.**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** VYD222

## Key facts

- **NCT ID:** NCT06004128
- **Lead sponsor:** Invivyd, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004128, "Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06004128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*